Human immunodeficiency virus, Mycobacterium tuberculosis, and pregnancy: A deadly combination

Clinical Infectious Diseases

Volumn 45, Issue 2, 2007, Pages 250-253

  Mofenson, Lynne M ^a   Laughon, Barbara E ^b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BCG VACCINE; GAMMA INTERFERON; ISONIAZID;

CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNITY; CYTOKINE RELEASE; DELIVERY; DISEASE ACTIVITY; DISEASE TRANSMISSION; HEPATITIS; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT MORTALITY; INFECTION RISK; LIFE EXPECTANCY; LIVER TOXICITY; MATERNAL MORTALITY; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NOTE; PREGNANCY; PREGNANT WOMAN; PREVALENCE; PRIORITY JOURNAL; SYMPTOMATOLOGY; TUBERCULIN TEST; TUBERCULOSIS; VERTICAL TRANSMISSION; VIRUS TRANSMISSION; AIDS RELATED COMPLEX; CAUSE OF DEATH; FEMALE; HOSPITALIZATION; INFANT; ISOLATION AND PURIFICATION; NEWBORN; PREGNANCY COMPLICATION; RISK ASSESSMENT; SURVIVAL;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; CAUSE OF DEATH; FEMALE; HIV; HUMANS; INFANT; INFANT MORTALITY; INFANT, NEWBORN; MATERNAL MORTALITY; MYCOBACTERIUM TUBERCULOSIS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TUBERCULOSIS;

EID: 34447098234     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/518975     Document Type: Note

References (42)

1. World Health Organization. TB/HIV: a clinical manual. 2nd ed. Geneva, Switzerland: World Health Organization, 2004.
2. Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication: role of immune activation. J Immunol 1996; 157:1271-6.
3. Lopez-Gatell H, Cole SR, Hessol NA, et al. Effect of tuberculosis on survival of women infected with human immunodeficiency virus. Am J Epidemiol 2007; 165:1134-42.
4. Allen S, Batungwanayo J, Kerlikowske K, et al. Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women. Am Rev Respir Dis 1992; 146:1439-44.
5. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus. N Engl J Med 1989; 320:545-50.
6. Corbett EL, Marston B, Churchyard GJ, deCock KM. Tuberculosis in sub-Saharan Africa: opportunities, challenges and change in the era of antiretroviral treatment. Lancet 2006; 367:926-36.
7. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet 2003; 362:887-99.
8. Pillay T, Khan M, Moodley J, Adhikari M, Coovadia H. Perinatal tuberculosis and HIV-1: considerations for resource-limited settings. Lancet Infect Dis 2004; 4:155-65.
9. World Health Organization. AIDS epidemic update: December 2006. Geneva, Switzerland: World Health Organization, 2007.
10. Connolly M, Nunn P. Women and tuberculosis. World Health Stat Q 1996; 49:115-9.
11. Holmes CAB, Hausler H, Nunn P. A review of sex differences in the epidemiology of tuberculosis. Int J Tuberc Lung Dis 1998; 2:96-104.
12. Diwan VK, Thorson A. Sex, gender, and tuberculosis. Lancet 1999; 353:1000-1.
13. Tripathy SN, Tripathy SN. Tuberculosis and pregnancy. Int J Gynaecol Obstet 2003; 80:247-53.
14. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: the Global Burden of Disease Study. Lancet 1997; 349:1269-76.
15. Pillay T, Khan M, Moodley J, et al. The increasing burden of tuberculosis in pregnant women, newborns and infants under 6 months of age in Durban, KwaZulu-Natal. S Afr Med J 2001; 91:983-7.
16. Espinal MA, Reingold AL, Lavandera M. Effect of pregnancy on risk of developing active tuberculosis. J Infect Dis 1996; 173:488-91.
17. Ormerod P. Tuberculosis in pregnancy and the puerperium. Thorax 2001; 56:494-9.
18. Khan M, Pillay T, Moodley JM, Connolly CA; for the Durban Perinatal TB HIV-1 Study Group. Maternal mortality associated with tuberculosis-HIV-1 co-infection in Durban, South Africa. AIDS 2001; 15:1857-63.
19. Ahmed Y, Mwaba P, Chintu C, et al. A study of maternal mortality at the University Teaching Hospital, Lusaka, Zambia: the emergence of tuberculosis as a major non-obstetric cause of maternal death. Int J Tuberc Lung Dis 1999; 3:675-80.
20. Gupta A, Nayak U, Ram M, et al. Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005. Clin Infect Dis 2007; 45:241-9 (in this issue).
21. Skevaki CL, Kafetzis DA. Tuberculosis in neonates and infants: epidemiology, pathogenesis, clinical manifestations, diagnosis and management issues. Paediatr Drugs 2005; 7:219-34.
22. Pillay T, Sturm AW, Khan M, et al. Vertical transmission of mycobacterium tuberculosis in KwaZulu-Natal: impact of HIV-1 co-infection. Int J Tuberc Lung Dis 2004; 8:59-69.
23. Adhikari M, Pillay T, Pillay DG. Tuberculosis in the newborn: an emerging disease. Pediatr Infect Dis J 1997; 16:1108-12.
24. Drobac PC, del Castillo H, Sweetland A, et al. Treatment of multidrug-resistant tuberculosis during pregnancy: long-term follow-up of 6 children with intrauterine exposure to second-line agents. Clin Infect Dis 2005; 40:1689-92.
25. Figueroa-Damian R, Arredondo-Garcia JL. Neonatal outcome of children born to women with tuberculosis. Arch Med Res 2001; 32:66-9.
26. Kali PB, Gray GE, Violari A, et al. Combining PMTCT with active case finding for tuberculosis. JAIDS 2006; 42:379-81.
27. Nachega J, Coetzee J, Adendorff, T et al. Tuberculosis active case finding in a mother-to-child HIV transmission prevention program in Soweto, South Africa. AIDS 2003; 17:1398-400.
28. Blumberg HM, Leonard MK, Jasmer RM. Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA 2005; 293:2776-84.
29. Connell TG, Rangada MX, Curtis N, Wilkinson RJ. QuantiFERON-TB Gold: state of the art for the diagnosis of tuberculosis infection? Expert Rev Mol Diagn 2006; 6:663-77.
30. STOP-TB Partnerhip Childhood TB Subgroup, World Health Organization. Chapter 4: childhood contact screening and management. Int J Tuberc Lung Dis 2007; 11:12-5.
31. Bucher HC, Griffith LE, Guyatt GH, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 1999; 13:501-7.
32. Grant AD, Charalambous S, Fielding KL, et al. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. JAMA 2005; 293:2719-25.
33. Elzi L, Schlegel M, Weber R, et al. Reducing tuberculosis incidence by tuberculin skin test-ing, preventive treatment and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis 2007; 44:94-102.
34. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Recomm Rep 1998; 47(RR-20):1-58.
35. Franks A, Binkin N, Snider D, Rokaw W, Becker S. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep 1989; 104:151-5.
36. Snider DE, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Resp Dis 1992; 145:494-7.
37. Sackoff JE, Pfeiffer MR, Driver CR, et al. Tuberculosis prevention for non-US-born pregnant women. Am J Obstet Gynecol 2006; 194:451-6.
38. Boggess KA, Myers ER, Hamilton CD. Antepartum or postpartum isoniazid treatment of latent tuberculosis treatment. Obstet Gynecol 2000; 96:757-62.
39. Lim HJ, Okwera A, Mayanja-Kizza H, et al. Effect of tuberculosis preventive therapy on HIV disease progression and survival in HIV-infected adults. HIV Clin Trials 2006; 7:172-83.
40. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359:2059-64.
41. Santoro-Lopes G, de Pinho AM, Harrison LH, Schechter M. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 2002; 34:543-6.
42. Jones JI, Hanson DL, Dworkin MS, de Cock KM. HIV-associated TB in the era of HAART. Int J Tuberc Lung Dis 2000; 4:1026-31.